Latest studies
- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study in healthy people to compare how 3 different formulations of survodutide are taken up in the body
This study is looking at how a new medicine, called survodutide, works in healthy people. We want to see how different forms of the medicine are absorbed by the body. This helps us learn more about how to give the medicine effectively.
Healthy volunteer trialGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicentre open-label study to explore the effects of sonelokimab in patients with moderate-to-severe pustulosis palmoplantaris
This study is looking at a new medicine called sonelokimab for people with a skin condition called palmoplantar pustulosis (PPP). It wants to see how well the medicine works to reduce the redness and spots on hands and feet after 16 weeks.
Palmoplantar PustulosisGermany - Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
This study is gathering important information about a rare kidney disease called atypical Hemolytic-Uremic Syndrome (aHUS). It looks at how the disease progresses and how safe new treatments like eculizumab and ravulizumab are for patients of all ages.
Atypical Hemolytic-Uremic SyndromeGermany - AuthorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
This study is testing a new weekly pill for HIV to see if it's as good as a daily pill people already take. It's for adults whose HIV is already under control. We want to check how safe and effective the new weekly treatment is.
HIV-1 InfectionGermany - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal AdenocarcinomaGermany - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesityGermany - Active not recruitingPHASE4
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
This study looks at a medicine called OM-85 to see if it can help young children, aged 6 months to 5 years, who get lots of chest infections and wheezing. We want to know if it's safe and effective at reducing how often they get ill.
Respiratory Tract InfectionsWheezing Lower Respiratory IllnessGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
This study is looking at new eye drops for people with an eye condition called Fuchs Endothelial Corneal Dystrophy. It checks if the drops help people see better after cataract surgery and another eye procedure. The study lasts about a year.
Fuchs Endothelial Corneal DystrophyGermany - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Germany - Active not recruitingPHASE2
Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
This study is testing a new weekly drug called rezafungin for adults with a serious lung infection called Chronic Pulmonary Aspergillosis (CPA). It's for people who haven't found other treatments effective or can't take them. We want to see if it's safe and helps improve their health over six months.
Chronic Pulmonary AspergillosisGermany - Active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
Neoplasm MalignantRenal Cell CarcinomaHormone Receptor Positive Breast CarcinomaMetastatic Castration-resistant Prostate CancerGermany - RecruitingPHASE2
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
This study is testing a new medicine, GSK4532990, for people aged 18-70 with liver damage caused by alcohol. We want to see if it's safe and if it helps the liver. Some people will get the medicine, others a dummy pill.
Liver Diseases, AlcoholicGermany - AuthorisedPhase II and Phase III (Integrated)
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
This study looks at new ways to treat a type of skin cancer in the eye that has spread (metastatic uveal melanoma). It compares two drug combinations, RP2 with Nivolumab, against Ipilimumab with Nivolumab, to see which is safer and more effective.
metastatic uveal melanomaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
Study 1002-041: An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) with Heterozygous Familial Hypercholesterolemia
This study is looking at a medicine called bempedoic acid for children and teenagers aged 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia. We want to see how the medicine works in their bodies and if it's safe.
Heterozygous familial hypercholesterolemia, Heterozygous Familial HypercholesterolemiaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
This study looks at a new drug combination for Primary Biliary Cholangitis (PBC). It checks if mixing two existing medicines, Obeticholic Acid and Bezafibrate, helps liver health over a long time. Researchers want to see how safe and effective this combination is for patients.
Primary Biliary Cholangitis (PBC)Germany - AuthorisedTherapeutic exploratory (Phase II)
A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases
This study looks at new ways to treat advanced melanoma, a type of skin cancer. It combines a standard cancer drug, pembrolizumab, with injections directly into the cancer. Researchers want to see if these new combinations can shrink tumours in people whose cancer hasn’t responded well to previous treatments.
Germany - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaGermany - RecruitingPHASE3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
This study is testing a new medicine, volrustomig, for people with a type of head and neck cancer that hasn't spread and wasn't removed by surgery. It aims to see if volrustomig helps prevent the cancer from coming back after standard treatment like chemotherapy and radiotherapy.
Locally Advanced Head and Neck Squamous Cell CarcinomaGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking at a new medicine called Vyvgart for people with Thyroid Eye Disease. It aims to see if the medicine can help reduce bulging eyes and improve eye health, compared to a dummy medicine, over 24 weeks.
Thyroid Eye Disease (TED)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma: a randomized phase II study (Ravina)
This study looks at a new drug, xevinapant, given with radiotherapy for older patients with advanced head and neck cancer. We want to see if this combination helps more people live longer without their cancer coming back. It's a Phase II study, meaning we're testing its effectiveness and safety.
Squamous cell carcinoma of head and neckGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
PHASE 2a OPEN-LABEL BASKET STUDY TO EVALUATE SAFETY AND PHARMACOKINETICS OF INF904, AN ORAL C5aR1 INHIBITOR, IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA OR HIDRADENITIS SUPPURATIVA
This study is testing a new medicine called INF904 for people with chronic hives or hidradenitis suppurativa. Researchers want to see if it's safe, how much stays in the body, and if it causes any side effects. It's an early-stage study to learn more about this new treatment.
Moderate to Severe Chronic Spontaneous Urticaria (CSU) or Moderate to Severe Hidradenitis Suppurativa (HS)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression
This study is testing a new nasal spray, BPL-003, for people with depression that hasn't responded to other treatments. Researchers are looking at different doses to see how well it works and if it's safe.
Treatment-Resistant Depression (TRD)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)
This study is looking into a new medicine called SerpinPC for severe haemophilia A or B. It wants to see if SerpinPC can reduce bleeding in adults with these conditions, especially those who currently treat bleeds as they happen. Researchers will also check how safe the new medicine is.
Severe Hemophilia A or Moderately Severe to Severe Hemophilia BGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Proof-of-Concept, Open-label Study to Assess the Safety and Efficacy of Batoclimab in Participants with Graves’ Disease (GD)
This study is testing a new medicine, Batoclimab, for Graves' disease. Researchers want to see if it's safe and helps control thyroid hormone levels, aiming for them to be normal or lower, without needing more of current thyroid medication.
Grave's diseaseGermany - Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
This study is gathering information on a rare genetic condition called LAL Deficiency. It aims to understand the disease better and improve care for affected individuals, from babies to adults. It's a worldwide effort to collect health data over time.
Lysosomal Acid Lipase DeficiencyCholesterol Ester Storage DiseaseWolman DiseaseAcid Cholesteryl Ester Hydrolase Deficiency, Type 2Germany - RecruitingPHASE2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Imeroprubart, for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyGermany - Active not recruitingPHASE2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
This study looks at a new drug, tulisokibart, for people with a lung condition called interstitial lung disease (ILD) linked to scleroderma. We want to see if it's safe and helps improve the condition.
Diffuse Cutaneous Systemic SclerosisInterstitial Lung DiseaseGermany - Ongoing, recruitingPhase III and phase IV (Integrated)
A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab
This study is looking at a new treatment called teprotumumab for Thyroid Eye Disease. It aims to safely see if different lengths of taking the medicine affect how well it works and if people need further treatment later.
Thyroid Eye DiseaseGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment-naïve Pediatric Participants with Infantile-Onset Pompe Disease (IOPD)
This study is testing a new medicine, Nexviadyme, for babies with a rare genetic condition called Pompe disease. It aims to see if the medicine helps them breathe better and grow, and if it's safe, especially for those who haven't tried other treatments.
Glycogen storage disease type IIGermany - Active not recruitingPHASE3
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
This study is testing a new medicine, selumetinib, for adults with a condition called Neurofibromatosis Type 1 (NF1). It focuses on people who have painful, non-removable growths called plexiform neurofibromas. We want to see if this medicine can help reduce symptoms and safely shrink these growths.
Neurofibromatosis 1Plexiform Neurofibroma (PN)Germany - Active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
Muscle-invasive Bladder CancerGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking into a new treatment called Efgartigimod for Thyroid Eye Disease (TED). Researchers want to see how well it works, if it's safe, and if it causes any side effects. It's a big study involving many people, with some receiving the new drug and others a dummy treatment.
Thyroid Eye Disease (TED)Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)
This study looks at a new medicine called BH-200 for adults with severe depression. It compares BH-200 to a dummy pill to see if it helps improve mood and daily life better, and if it's safe.
Major Depressive DisorderGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Obesity, Chronic Kidney disease, Type 2 Diabetes, Cardiovascular Diseases, Overweight or Obesity, OverweightGermany - Active not recruitingPHASE3
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
This study looks at treating muscle-invasive bladder cancer. It compares standard chemotherapy with chemotherapy plus a new immunotherapy drug called nivolumab, given before and after surgery. The aim is to see if adding nivolumab helps more people.
Urinary Bladder NeoplasmsMuscle-Invasive Bladder CancerGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
This study is testing a new medicine, MK-2060, to see if it can stop blood clots forming in special tubes (grafts) used for kidney dialysis. We want to know if it's safe and if it works better than a dummy medicine (placebo) for people with serious kidney disease.
Prevention of arteriovenous graft thrombosisGermany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory BCell Non Hodgkin Lymphoma (ZUMA-4)
This study is testing a new treatment called Tecartus for children and teenagers with certain types of blood cancer (leukaemia and lymphoma) that have come back after treatment. We want to see how safe it is and how well it works to help patients get better.
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
This study compares two treatments, Lutetium-177 rhPSMA-10.1 and Pluvicto, for men with advanced prostate cancer that has spread. Researchers want to see which treatment delivers more helpful radiation to the cancer and less to healthy body parts like the kidneys.
PSMA-positive non-curative metastatic castration-resistant prostate cancerGermany - Active not recruitingPHASE3
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
This study is looking at a new medicine called efanesoctocog alfa (BIVV001) for people with haemophilia A. It aims to see if it's safe and effective over a long time in preventing and treating bleeds, improving joint health and quality of life.
Hemophilia AGermany - Active not recruitingNA
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
This study is looking at a new treatment called Targeted Lung Denervation (TLD) for people with a lung condition called COPD. It aims to see if TLD is safe and works better than standard care to reduce flare-ups of COPD symptoms.
COPDGermany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn how much elinzanetant gets into the blood, how safe it is and how it affects the body after taking single and multiple amounts in healthy subjects
This study is looking at a new medicine called elinzanetant. It wants to find out how much of it gets into your body, if it's safe, and what effects it has. The study is for healthy adults, and it's an early step in understanding this new drug.
Vasomotor Symptoms as a sex hormone-dependent disorder in women and menGermany - Recruiting
EURO-STIM Registry
This study looks at how well the Inspire System works for people with Obstructive Sleep Apnoea (OSA) over time. It collects information from patients using the device during their regular clinic visits to understand its long-term benefits and how people manage with it.
Obstructive Sleep ApneaObstructive Sleep Apnea (OSA)Germany - AuthorisedPhase I and Phase II (Integrated)- Other
A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma.
This study is testing a new antibody treatment, L19TNF, along with standard brain cancer medication, temozolomide. It aims to see if combining them is safe and helps people with a type of brain tumour called glioblastoma live longer and feel better.
GlioblastomaGermany - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
This study is testing a new combination medicine (MK-4280A) against standard chemotherapy for people with Hodgkin Lymphoma that has come back or not responded to previous treatments. We want to see if the new medicine can stop the cancer from growing for longer.
Relapsed or Refractory Classical Hodgkin LymphomaGermany - AuthorisedPhase II and Phase III (Integrated)
An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition
This study is for children aged 3-18 with a type of brain tumour called medulloblastoma. It looks at different ways to treat the tumour, including various chemotherapy drugs, to find the most effective and safest options for different types of medulloblastoma, aiming to improve chances of recovery and quality of life.
MedulloblastomaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
J3P-MC-FTAF: An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
This study is testing a new medicine, LY3871801, for adults with rheumatoid arthritis. It's a research study to see how well the medicine works and if it's safe compared to a dummy pill. We hope to find new ways to help people with this condition.
Rheumatoid ArthritisGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
This study is testing a new combination of medicines for people with a type of breast cancer called triple-negative breast cancer that has spread or can't be removed with surgery. It aims to see if the new combination can help people live longer without their cancer getting worse.
Triple-Negative Breast Cancer (TNBC)Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)
This study is looking for the best dose of a new medicine called BI 907828 (brigimadlin) for people with advanced cancers that have grown or spread. It's an early-stage study to understand how the medicine works in the body.
Advanced or metastatic solid tumorsGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCB 18424-319: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Purigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN1)
This study is testing a new cream for Prurigo Nodularis, a skin condition causing very itchy bumps. It compares a cream with the active medicine to a plain cream, to see if the new medicine can help reduce itchiness and improve the skin condition over 12 weeks.
Prurigo NodularisGermany